Inhibikase Therapeutics, Inc. IKT
1.38 USD -0.07 (-4.83%)
Regular-session close
1.38 0.00 0.00%
After hours · Nov 17, 4:01 PM ET
1.37 Day range 1.49
1.37 52-week range 2.61
- YTD
- -32.68%
- 1 year
- -9.21%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $8 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and maintains $8 price target.
globenewswire.com Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity WILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel…
globenewswire.com Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026 WILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel…
globenewswire.com Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel…
globenewswire.com Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WILMINGTON, Del., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to…
defenseworld.net Critical Survey: Inhibikase Therapeutics (NASDAQ:IKT) and Otsuka (OTCMKTS:OTSKY) Otsuka (OTCMKTS:OTSKY - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two…
defenseworld.net Financial Review: Inhibikase Therapeutics (NASDAQ:IKT) vs. Eli Lilly and Company (NYSE:LLY) Eli Lilly and Company (NYSE: LLY - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the…
globenewswire.com Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel…
defenseworld.net ADAR1 Capital Management LLC Reduces Stock Position in Inhibikase Therapeutics, Inc. $IKT ADAR1 Capital Management LLC reduced its stake in Inhibikase Therapeutics, Inc. (NASDAQ: IKT) by 18.1% in the first quarter, according to its most recent Form 13F filing with the Securities and…
globenewswire.com Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary…
globenewswire.com Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary…
globenewswire.com Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to…
globenewswire.com Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary…
globenewswire.com Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary…
globenewswire.com Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to…
globenewswire.com Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify…
defenseworld.net Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Up 52.2% in February Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 27th, there was short interest…
defenseworld.net Analyzing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP) Inhibikase Therapeutics (NYSE: IKT - Get Free Report) and Big Cypress Acquisition (OTCMKTS:BCYP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will…
defenseworld.net Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of “Buy” from Analysts Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) has been given a consensus recommendation of "Buy" by the five research firms that are currently covering the stock, Marketbeat Ratings…
defenseworld.net Comparing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP) Big Cypress Acquisition (OTCMKTS:BCYP - Get Free Report) and Inhibikase Therapeutics (NYSE: IKT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will…
defenseworld.net Comparing Liminatus Pharma (NASDAQ:LIMN) & Inhibikase Therapeutics (NASDAQ:IKT) Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will…
